MedTrace Logo

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

NCT00882882 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-03-29

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.

Conditions

  • Type II Diabetes

Interventions

DRUG

Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC

DRUG

Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC

DRUG

GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

DRUG

GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

Sponsors & Collaborators

Principal Investigators

  • So Ran Hong, M.D. · Novum Independent Institutional Review Board

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2001-06-30
Completion
2001-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00882882 on ClinicalTrials.gov